From: Tolerance and rebound with zafirlukast in patients with persistent asthma
ICS-treated + Placebo Change from baseline | ICS-treated + Zafirlukast Change from baseline | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Baseline (N = 8) | Weeks 0–5 (N = 8) | Weeks 6–10 (N = 8) | Week 11–12 (N = 8) | *W/D (N = 8) | Baseline (N = 15) | Weeks 0–5 (N = 15) | Weeks 6–10 (N = 13) | Week 11–12 (N = 13) | *W/D (N = 11) | |
PEFR a.m., L/min | 353 (± 32.3) | +13.9 (± 6.1) | +21.1 (± 9.6) | +17.5 (± 12.2) | +10.4 (± 6.6) | 389 (± 21.2) | +15.7 (± 5.0) | +16.7 (± 6.1) | +2.7 (± 15.2) | -7.4 (± 6.3) |
PEFR p.m., L/min | 373 (± 32.8) | +9.4 (± 10.0) | +6.4 (± 15.0) | +17.7 (± 12.1) | +5.3 (± 6.2) | 404 (± 20.0) | +10.5 (± 4.9) | +10.9 (± 5.8) | -0.6 (± 15.0) | -23.1 (± 6.6) |
FEV1, mL | 2,567 (± 225) | -134 (± 67.7) | -130 (± 47.2) | -23.8 (± 93.6) | +78.8 (± 59.6) | 2,540 (± 179) | +105 (± 72.5) | -39.2 (± 74.7) | +144 (± 106) | -94.5 (± 48.0) |
β2-agonist use per day | 3.9 (± 0.6) | -0.8 (± 0.47) | -1.2 (± 0.68) | -0.3 (± 1.0) | -0.4 (± 0.4) | 3.7 (± 0.5) | -0.8 (± 0.25) | -0.9 (± 0.32) | -1.1 (± 0.4) | +0.6 (± 0.47) |
Severity score | 2.0 (± 0.02) | -0.3 (± 0.1) | -0.3 (± 0.1) | -0.03 (± 0.04) | -0.1 (± 0.1) | 1.8 (± 0.7) | -0.3 (± 0.1) | -0.3 (± 0.1) | -0.4 (± 0.2) | +0.1 (± 0.2) |
**Total mornings | 5.7 (± 0.8) | -1.8 (± 0.8) | -3.2 (± 0.9) | -2.3 (± 1.4) | -0.8 (± 2.2) | 3.2 (± 0.6) | -0.7 (± 0.4) | -1.1 (± 0.7) | -0.6 (± 0.5) | +0.4 (± 0.3) |
**Total awakenings | 1.5 (± 0.9) | -0.8 (± 0.7) | -0.8 (± 0.5) | -1.1 (± 0.7) | +0.4 (± 1.1) | 1.8 (± 0.7) | -0.6 (± 0.5) | -0.9 (± 0.6) | -1.6 (± 0.7) | +1.4 (± 1.0) |